Nektar Therapeutics

Nektar trades with a 13.4% short interest—notably elevated for a biotech name—while its RSI of 43 sits comfortably in neutral territory, suggesting neither oversold nor overbought conditions. The absence of a P/E ratio signals the company isn't yet profitable, typical for development-stage pharma, though the $2.8B market cap implies substantial investor confidence in its pipeline. With the stock trading well below its 52-week highs and significant short positioning, there's potential vulnerability to either a disappointing catalyst or a squeeze if clinical data proves positive. The setup appears precarious for a biotech: meaningful downside risk if trials underwhelm, but equally meaningful upside if shorts need covering amid positive news.